Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin

Background Bitopertin (RG1678) is a glycine reuptake inhibitor currently in phase 3 trials for treatment of schizophrenia. This paper describes the use of physiologically based pharmacokinetic (PBPK) modelling and preclinical data to gain insights into and predict bitopertin clinical pharmacokinetic...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacokinetics 2013-08, Vol.52 (8), p.673-683
Main Authors: Parrott, Neil, Hainzl, Dominik, Alberati, Daniela, Hofmann, Carsten, Robson, Richard, Boutouyrie, Bruno, Martin-Facklam, Meret
Format: Article
Language:English
Subjects:
Adolescent
Adult
Animals
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - pharmacokinetics
Biological and medical sciences
Dose-Response Relationship, Drug
Double-Blind Method
General pharmacology
Glycine Plasma Membrane Transport Proteins - antagonists & inhibitors
Hepatocytes - metabolism
Humans
Internal Medicine
Macaca fascicularis
Male
Medical sciences
Medicine
Medicine & Public Health
Models, Biological
Original Research Article
Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions
Pharmacology. Drug treatments
Pharmacology/Toxicology
Pharmacotherapy
Piperazines - administration & dosage
Piperazines - pharmacokinetics
Rats
Rats, Wistar
Sulfones - administration & dosage
Sulfones - pharmacokinetics
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Bitopertin (RG1678) is a glycine reuptake inhibitor currently in phase 3 trials for treatment of schizophrenia. This paper describes the use of physiologically based pharmacokinetic (PBPK) modelling and preclinical data to gain insights into and predict bitopertin clinical pharmacokinetics. Methods Simulations of pharmacokinetics were initiated early in the drug discovery stage by integrating physicochemical properties and in vitro measurements into a PBPK rat model. Comparison of pharmacokinetics predicted by PBPK modelling with those measured after intravenous and oral dosing in rats and monkeys showed a good match and thus increased confidence that a similar approach could be applied for human prediction. After comparison of predicted plasma concentrations with those measured after single oral doses in the first clinical study, the human model was refined and then applied to simulate multiple-dose pharmacokinetics. Results Clinical plasma concentrations measured were in good agreement with PBPK predictions. Predicted area under the plasma concentration–time curve (AUC) was within twofold of the observed mean values for all dose levels. Maximum plasma concentration ( C max ) at higher doses was well predicted but approximately twofold below observed values at the lower doses. A slightly less than dose-proportional increase in both AUC and C max was observed, and model simulations indicated that when the dose exceeded 50 mg, solubility limited the fraction of dose absorbed. Refinement of the absorption model with additional solubility and permeability measurements further improved the match of simulations to observed single-dose data. Simulated multiple-dose pharmacokinetics with the refined model were in good agreement with observed data. Conclusions Clinical pharmacokinetics of bitopertin can be well simulated with a mechanistic PBPK model. This model supports further clinical development and provides a valuable repository for pharmacokinetic knowledge gained about the molecule.
ISSN:0312-5963
1179-1926
DOI:10.1007/s40262-013-0061-x